Taiwanese pharma company Twi Pharmaceuticals has appointed Tina Guilder as president and chief executive officer.
The current president, Calvin Chen, will become Ms Guilder’s special adviser and remain as president of Twi Biotechnology. The board has also decided to appoint Eva Ho as the chief financial officer of the company.
Prior to joining Twi, Ms Guilder was the vice president of business development and alliance management at Teva Pharmaceuticals USA (NYSE: TEVA), and has more than 18 years of experience in the pharma and healthcare industry, with emphasis on finance.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze